Hyperhomocysteinaemia and factor V Leiden mutation are associated with Budd-Chiari syndrome

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 8, 2006, Pages 917-920

  Colak, Yusuf ^a   Karasu, Zeki ^a   Oruc, Nevin ^a   Can, Cenk ^a   Balým, Zuhal ^a   Akarca, UlusSalih ^a   Gunsar, Fulya ^a   Ersoz, Galip ^a   Tokat, Yaman ^a   Batur, Yucel ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Budd Chiari; Factor V Leiden; Hyperhomocysteinaemia; Prothrombin

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; ANGIOGRAPHY; ARTICLE; BUDD CHIARI SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DISEASE ASSOCIATION; DNA EXTRACTION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE DETECTION; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; MONONUCLEAR CELL; MUTAGENESIS; MUTATION RATE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADULT; BUDD-CHIARI SYNDROME; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HEPATIC VEIN THROMBOSIS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTHROMBIN; SEX FACTORS; TURKEY;

EID: 33745844816     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200608000-00019     Document Type: Article

References (21)

1. Dilawari JB, Bambery P, Chawla Y. Hepatic outflow obstruction (Budd-Chiari syndrome): experience with 177 patients and a review of the literature. Medicine 1994; 73:21-36.
2. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee M. Promotion of vascular smooth muscle cell growth by homocysteine: a link arteriosclerosis. Proc Natl Acad Sci 1994; 91:6369-6373.
3. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18:113-121.
4. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13:1327-1333.
5. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses heperan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92:1381-1386.
6. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullman D, et al. A prospective study of serum total homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-881.
7. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of total serum homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395-1398.
8. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286-291.
9. den Heijer M, Koster T, Blom HJ, Bos BM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762.
10. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, Di Minno G. Hyperhomocysteinemia and other inherited prothrombotic condition in young adults with a history of ischemic stroke. Stroke 2002; 33:51-56.
11. Li XM, Wei YF, Hao HL, Hao YB, He LS, Li JD et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol 2002; 71:11-14.
12. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96:2364-2368.
13. Mahmoud AEA, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40:798-800.
14. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3 untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996; 88:3698-3703.
15. Bertina RM, Koeleman BPC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
16. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide from homocysteine. J Clin Invest 1986; 77:1370-1376.
17. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effect of homocysteine is modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308-318.
18. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693.
19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-917.
20. Reiner AP, Rosendaal FR, Reitsma PH, Lemaitre RN, Pearce RM, Friedlander Y, et al. Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol 2002; 90:66-68.
21. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95:1777-1782.